{
  "actions": [
    {
      "acted_at": "2019-05-23", 
      "action_code": "10000", 
      "references": [], 
      "text": "Introduced in Senate", 
      "type": "action"
    }, 
    {
      "acted_at": "2019-05-23", 
      "action_code": "", 
      "committees": [
        "SSHR"
      ], 
      "references": [], 
      "status": "REFERRED", 
      "text": "Read twice and referred to the Committee on Health, Education, Labor, and Pensions.", 
      "type": "referral"
    }
  ], 
  "amendments": [], 
  "bill_id": "s1662-116", 
  "bill_type": "s", 
  "by_request": false, 
  "committee_reports": [], 
  "committees": [
    {
      "activity": [
        "referral"
      ], 
      "committee": "Senate Health, Education, Labor, and Pensions", 
      "committee_id": "SSHR"
    }
  ], 
  "congress": "116", 
  "cosponsors": [], 
  "enacted_as": null, 
  "history": {
    "active": false, 
    "awaiting_signature": false, 
    "enacted": false, 
    "vetoed": false
  }, 
  "introduced_at": "2019-05-23", 
  "number": "1662", 
  "official_title": "A bill to establish an annual fee applicable to opioid manufacturers.", 
  "popular_title": null, 
  "related_bills": [
    {
      "bill_id": "hr3105-116", 
      "identified_by": "CRS", 
      "reason": "identical", 
      "type": "bill"
    }
  ], 
  "short_title": "Opioid Treatment Surge Act", 
  "sponsor": {
    "bioguide_id": "M001176", 
    "district": null, 
    "name": "Merkley, Jeff", 
    "state": "OR", 
    "title": "Sen", 
    "type": "person"
  }, 
  "status": "REFERRED", 
  "status_at": "2019-05-23", 
  "subjects": [
    "Drug, alcohol, tobacco use", 
    "Health", 
    "Health care coverage and access", 
    "Prescription drugs", 
    "User charges and fees"
  ], 
  "subjects_top_term": "Health", 
  "summary": {
    "as": "Introduced in Senate", 
    "date": "2019-05-23T04:00:00Z", 
    "text": "Opioid Treatment Surge ActThis bill requires the Department of Health and Human Services to assess market-share-based fees, for the next 10 years, on drug manufacturers that have produced opioid drugs since 1999. Opioid drugs manufactured to treat opioid addiction, cancer patients, or hospice patients are, however, exempt from this assessment. All assessed fees must be used for the substance abuse prevention and treatment block grant program."
  }, 
  "titles": [
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "A bill to establish an annual fee applicable to opioid manufacturers.", 
      "type": "official"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Opioid Treatment Surge Act", 
      "type": "short"
    }, 
    {
      "as": "introduced", 
      "is_for_portion": false, 
      "title": "Opioid Treatment Surge Act", 
      "type": "short"
    }, 
    {
      "as": null, 
      "is_for_portion": false, 
      "title": "Opioid Treatment Surge Act", 
      "type": "display"
    }
  ], 
  "updated_at": "2019-10-26T10:03:05Z", 
  "url": "https://www.govinfo.gov/bulkdata/BILLSTATUS/116/s/BILLSTATUS-116s1662.xml"
}